{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:21:57Z","timestamp":1790774517614,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T00:00:00Z","timestamp":1586304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00419","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:54:37Z","timestamp":1586321677000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Daniel P.","family":"Zimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney M.","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny V.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Tchernychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Germano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali R.","family":"Banijamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie G.","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh-tyng","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Graul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavrielle M.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Chickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Todd","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Currie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime L.","family":"Masferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1073\/pnas.0304264101","article-title":"Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment","volume":"101","author":"Ahluwalia","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.15420\/cfr.2016:3:3","article-title":"Nitrates as a Treatment of Acute Heart Failure","volume":"2","author":"Alzahri","year":"2016","journal-title":"Card. Fail. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/JOE-11-0122","article-title":"Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats","volume":"210","author":"Bilan","year":"2011","journal-title":"J. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.17235\/reed.2017.4575\/2016","article-title":"Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome","volume":"109","author":"Borges Canha","year":"2017","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"B5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1006\/bbrc.1999.1444","article-title":"Tissue distribution of the human soluble guanylate cyclases","volume":"263","author":"Budworth","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.niox.2018.05.009","article-title":"Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential","volume":"78","author":"Buys","year":"2018","journal-title":"Nitric. Oxide"},{"key":"B7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","article-title":"Structure and regulation of soluble guanylate cyclase","volume":"81","author":"Derbyshire","year":"2012","journal-title":"Ann. Rev. Biochem."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181861","article-title":"High resolution molecular and histological analysis of renal disease progression in ZSF1 fa\/faCP rats, a model of type 2 diabetic nephropathy","volume":"12","author":"Dower","year":"2017","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ki.1986.45","article-title":"The biology of renal hypertrophy","volume":"29","author":"Fine","year":"1986","journal-title":"Kidney Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2125.2005.02553.x","article-title":"Tadalafil pharmacokinetics in healthy subjects","volume":"61","author":"Forgue","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Galie","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0021853","article-title":"Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive dahl rats","volume":"6","author":"Geschka","year":"2011","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"F1605","DOI":"10.1152\/ajprenal.00511.2006","article-title":"Dynamic blood pressure load and nephropathy in the ZSF1 (fa\/fa cp) model of type 2 diabetes","volume":"293","author":"Griffin","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"6S","DOI":"10.1016\/j.amjmed.2003.09.009","article-title":"Hyperglycemia as a cardiovascular risk factor","volume":"115","author":"Haffner","year":"2003","journal-title":"Am. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00125-019-05062-x","article-title":"An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension","volume":"63","author":"Hanrahan","year":"2020","journal-title":"Diabetologia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1038\/ncomms8235","article-title":"Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue","volume":"6","author":"Hoffmann","year":"2015","journal-title":"Nat. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1476-9255-9-28","article-title":"Inhibition of nitric oxide synthesis enhances leukocyte rolling and adhesion in human microvasculature","volume":"9","author":"Hossain","year":"2012","journal-title":"J. Inflamm. (Lond.)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1073\/pnas.88.11.4651","article-title":"Nitric oxide: an endogenous modulator of leukocyte adhesion","volume":"88","author":"Kubes","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1161\/01.RES.43.2.170","article-title":"Baroreceptor reflexes in human hypertension","volume":"43","author":"Mancia","year":"1978","journal-title":"Circ. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/cmdc.200900014","article-title":"Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension","volume":"4","author":"Mittendorf","year":"2009","journal-title":"ChemMedChem"},{"key":"B24","first-page":"3533","article-title":"Multiple-ascending-dose study of the soluble guanylate cyclase stimulator, IW-1701 in healthy subjects","volume-title":"Blood","author":"Mittleman","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1021\/acsmedchemlett.5b00479","article-title":"Discovery of IWP-051, a novel orally bioavailable sGC Stimulator with once-daily dosing potential in humans","volume":"7","author":"Nakai","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00395-018-0679-9","article-title":"cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway","volume":"113","author":"Park","year":"2018","journal-title":"Basic Res. Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/CIRCULATIONAHA.113.004194","article-title":"Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT","volume":"128","author":"Rubin","year":"2013","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/FJC.0000000000000561","article-title":"Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction","volume":"71","author":"Salah","year":"2018","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/164_2018_197","article-title":"Soluble Guanylate Cyclase Stimulators and Activators","volume-title":"Handb. Exp. Pharmacol","author":"Sandner","year":"2018"},{"key":"B31","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-Independent, Haem-Dependent Soluble Guanylate Cyclase Stimulators","volume":"191","author":"Stasch","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence","volume":"21","author":"Stasch","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1124\/jpet.117.247429","article-title":"Pharmacological characterization of IW-1973, a novel soluble guanylate cyclase stimulator with extensive tissue distribution, antihypertensive, anti-inflammatory, and antifibrotic effects in preclinical models of disease","volume":"365","author":"Tobin","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1081\/JDI-100100882","article-title":"Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats","volume":"22","author":"Tofovic","year":"2000","journal-title":"Ren. Fail."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.biotechadv.2018.04.006","article-title":"Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways","volume":"36","author":"Wang","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"B37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1046\/j.1523-1755.1999.00590.x","article-title":"Molecular mechanisms of diabetic renal hypertrophy","volume":"56","author":"Wolf","year":"1999","journal-title":"Kidney Int."},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2017.06.010","article-title":"Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro","volume":"810","author":"Yamamura","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2147\/DMSO.S15323","article-title":"TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats","volume":"4","author":"Zambad","year":"2011","journal-title":"Diabetes Metab. Syndr. Obes."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00419\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:54:39Z","timestamp":1586321679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00419\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,8]]},"references-count":39,"alternative-id":["10.3389\/fphar.2020.00419"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00419","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,8]]},"article-number":"419"}}